Mabpharm Limited (2181) Stock Statistics & Valuation Metrics

Mabpharm Limited has a market cap or net worth of HK$1.63B. The enterprise value is HK$1.59B.

Mabpharm Limited has 4,124,080,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Mabpharm Limited’s return on equity (ROE) is 0.35 and return on invested capital (ROIC) is 0.55%.

The current PE Ratio of Mabpharm Limited is 26.7. Mabpharm Limited’s PEG ratio is -0.23.

In the last 12 months, Mabpharm Limited had revenue of 629.37M and earned 55.65M in profits. Earnings per share was 0.01.

In the last 12 months, operating cash flow was 80.78M and capital expenditures -104.00M, giving a free cash flow of -23.22M billion.

Mabpharm Limited pays an annual dividend of ―, resulting in a dividend yield of ―

Mabpharm Limited upcoming earnings date is Aug 21, 2026, TBA (Confirmed).

Mabpharm Limited as a current ratio of 0.81, with Debt / Equity ratio of 207.71%

In the past 12 months, Mabpharm Limited has paid -51.60M in taxes.

Mabpharm Limited EV to EBITDA ratio is 32.90, with an EV/FCF ratio of -89.15.

Mabpharm Limited has HK$109.30M in cash and marketable securities with HK$326.88M in debt, giving a net cash position of -HK$217.57M billion.

Gross margin is 85.91%, with operating margin of 0.74%, and net profit margin of 8.84%.

The average price target for Mabpharm Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―